Form 4 for URGN UroGen Pharma Ltd.
Accepted 2023-01-23 00:00:00 ET · period of report 2023-01-20 · accession 0001437749-23-001625 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-23 | 2023-01-20 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | $5.00 | +122.7K | 146.6K | +512% | +$613.4K |
| D | 2023-01-23 | 2023-01-20 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | $0.00 | -122.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-01-20 | M | A | 122,677 | $5.00 | 146,627 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-01-20 | M | D | 122,677 | $0.00 | 0 | D | $5.00 · 2019-01-20 to 2023-01-20 | 122,677 Ordinary Shares |